|
1
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stingl J and Caldas C: Molecular
heterogeneity of breast carcinomas and the cancer stem cell
hypothesis. Nat Rev Cancer. 7:791–799. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weigelt B, Peterse JL and van 't Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu S and Wicha MS: Targeting breast
cancer stem cells. J Clin Oncol. 28:4006–4012. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bhat-Nakshatri P, Goswami CP, Badve S,
Sledge GW Jr and Nakshatri H: Identification of FDA-approved drugs
targeting breast cancer stem cells along with biomarkers of
sensitivity. Sci Rep. 3:25302013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mukherjee S, Mazumdar M, Chakraborty S,
Manna A, Saha S, Khan P, Bhattacharjee P, Guha D, Adhikary A,
Mukhjerjee S and Das T: Curcumin inhibits breast cancer stem cell
migration by amplifying the E-cadherin/β-catenin negative feedback
loop. Stem Cell Res Ther. 5:1162014. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:pp.
3983–3988. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Williams K, Motiani K, Giridhar PV and
Kasper S: CD44 integrates signaling in normal stem cell, cancer
stem cell and (pre)metastatic niches. Exp Biol Med (Maywood).
238:324–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Besson A, Dowdy SF and Roberts JM: CDK
inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Casimiro MC, Crosariol M, Loro E, Li Z and
Pestell RG: Cyclins and cell cycle control in cancer and disease.
Genes Cancer. 3:649–657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Sullivan CC: Overcoming endocrine
resistance in hormone-receptor positive advanced breast cancer-the
emerging role of CDK4/6 inhibitors. Int J cancer Clin Res. 2:pii:
0292015. View Article : Google Scholar
|
|
14
|
Spring L, Bardia A and Modi S: Targeting
the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma
pathway with selective CDK 4/6 inhibitors in hormone
receptor-positive breast cancer: Rationale, current status, and
future directions. Discov Med. 21:65–74. 2016.PubMed/NCBI
|
|
15
|
DiPippo AJ, Patel NK and Barnett CM:
Cyclin-dependent kinase inhibitors for the treatment of breast
cancer: Past, present, and future. Pharmacotherapy. 36:652–667.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shapiro GI: Preclinical and clinical
development of the cyclin-dependent kinase inhibitor flavopiridol.
Clin Cancer Res. 10:4270s–4275s. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin TS, Ruppert AS, Johnson AJ, Fischer B,
Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, et al:
Phase II study of flavopiridol in relapsed chronic lymphocytic
leukemia demonstrating high response rates in genetically high-risk
disease. J Clin Oncol. 27:6012–6018. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carvajal RD, Tse A, Shah MA, Lefkowitz RA,
Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK and
O'Reilly EM: A phase II study of flavopiridol (alvocidib) in
combination with docetaxel in refractory, metastatic pancreatic
cancer. Pancreatology. 9:404–409. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soner BC, Aktug H, Acikgoz E, Duzagac F,
Guven U, Ayla S, Cal C and Oktem G: Induced growth inhibition, cell
cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem
cells by flavopiridol. Int J Mol Med. 34:1249–1256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Velasco-Velázquez MA, Homsi N, De La
Fuente M and Pestell RG: Breast cancer stem cells. Int J Biochem
Cell Biol. 44:573–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Skvortsova I, Debbage P, Kumar V and
Skvortsov S: Radiation resistance: Cancer stem cells (CSCs) and
their enigmatic pro-survival signaling. Semin Cancer Biol.
35:39–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lawson JC, Blatch GL and Edkins AL: Cancer
stem cells in breast cancer and metastasis. Breast Cancer Res
Treat. 118:241–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Charafe-Jauffret E, Ginestier C, Iovino F,
Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci
F, Jacquemier J, et al: Aldehyde dehydrogenase 1-positive cancer
stem cells mediate metastasis and poor clinical outcome in
inflammatory breast cancer. Clin Cancer Res. 16:45–55. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Senderowicz AM: Flavopiridol: The first
cyclin-dependent kinase inhibitor in human clinical trials. Invest
New Drugs. 17:313–320. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brighenti E, Treré D and Derenzini M:
Targeted cancer therapy with ribosome biogenesis inhibitors: A real
possibility? Oncotarget. 6:38617–38627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Newcomb EW, Tamasdan C, Entzminger Y,
Alonso J, Friedlander D, Crisan D, Miller DC and Zagzag D:
Flavopiridol induces mitochondrial-mediated apoptosis in murine
glioma GL261 cells via release of cytochrome c and apoptosis
inducing factor. Cell Cycle. 2:243–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van 't Veer LJ, Dai H, van de Vijver MJ,
He YD, Hart AA, Mao M, Peterse HL, Van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sherr CJ: The pezcoller lecture: Cancer
cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI
|
|
31
|
Kusnadi EP, Hannan KM, Hicks RJ, Hannan
RD, Pearson RB and Kang J: Regulation of rDNA transcription in
response to growth factors, nutrients and energy. Gene. 556:27–34.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Derenzini M, Montanaro L, Chillà A, Tosti
E, Vici M, Barbieri S, Govoni M, Mazzini G and Treré D: Key role of
the achievement of an appropriate ribosomal RNA complement for G1-S
phase transition in H4-II-E-C3 rat hepatoma cells. J Cell Physiol.
202:483–491. 2005. View Article : Google Scholar : PubMed/NCBI
|
